Liquidia Corporation Common Stock
LQDALiquidia Corporation (LQDA) is a biotechnology company focused on the development and commercialization of innovative products using its proprietary PRINT (Particle Replication in Non-wetting Templates) technology. The company's primary areas of interest include treatments in the fields of pulmonary, infectious, and other specialized diseases. Liquidia aims to improve drug delivery and therapeutic outcomes through its advanced particle engineering platform.
Company News
Liquidia Corporation will present two oral presentations at the CHEST 2025 annual meeting, focusing on clinical data from its ASCENT trial for LIQ861 DPI treprostinil in pulmonary hypertension-interstitial lung disease (PH-ILD) patients, highlighting safety and exploratory efficacy data.
The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.
The U.S. FDA has approved Liquidia's YUTREPIA, an inhaled dry-powder formulation of treprostinil, for the treatment of PAH and PH-ILD. The approval is based on the INSPIRE trial, which demonstrated YUTREPIA's safety, tolerability, and efficacy.
Liquidia Corporation announced that United Therapeutics filed a complaint alleging infringement of a patent related to inhaled treprostinil. Liquidia stated it has invalidated similar claims in the past and will continue to defend patients' access to its therapy.
The U.S. District Court for the District of Columbia dismissed a cross-claim filed by United Therapeutics that sought to challenge Liquidia's amendment to its New Drug Application for YUTREPIA, which added the treatment of pulmonary hypertension associated with interstitial lung disease to the proposed label. Liquidia remains focused on the poten...
